The CREST-E study of creatine for Huntington disease

@article{Hersch2017TheCS,
  title={The CREST-E study of creatine for Huntington disease},
  author={S. Hersch and G. Schifitto and D. Oakes and A. Bredlau and C. Meyers and R. Nahin and H. D. Rosas},
  journal={Neurology},
  year={2017},
  volume={89},
  pages={594 - 601}
}
Objective: To investigate whether creatine administration could slow progressive functional decline in adults with early symptoms of Huntington disease. Methods: We conducted a multicenter, randomized, double-blind, placebo-controlled study of up to 40 g daily of creatine monohydrate in participants with stage I and II HD treated for up to 48 months. The primary outcome measure was the rate of change in total functional capacity (TFC) between baseline and end of follow-up. Secondary outcome… Expand
Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis
TLDR
Efficacy of T80 ranked numerically superior to CRE and T40 with respect to ALSFRS-R decline, and T80 would be chosen to test against placebo following the selection paradigm. Expand
Baseline Variables Associated with Functional Decline in 2CARE: A Randomized Clinical Trial in Huntington's Disease.
TLDR
Variables associated with faster functional decline included worse motor performance, worse cognitive test scores, female sex, lower weight and body mass index, and a higher CAG repeat length, especially in younger people. Expand
Effects of Pridopidine on Functional Capacity in Early-Stage Participants from the PRIDE-HD Study
TLDR
Pridopidine 45 mg bid results in a nominally significant reduction in TFC decline at 52 weeks compared to placebo, particularly in patients with early-stage HD. Expand
Cross-sectional analysis of plasma and CSF metabolomic markers in Huntington’s disease for participants of varying functional disability: a pilot study
TLDR
The data suggest that defects in the urea cycle, glycine, and serine metabolism may be underrecognized in the progression HD pathology, and merit further study for possible therapeutic relevance. Expand
Huntington disease: A quarter century of progress since the gene discovery
TLDR
Better appreciation of heterogeneous clinical phenomenology and immediate tractable treatment goals coupled with advances in new therapeutics heralds a golden age of HD treatment that will positively impact quality of life and longevity of HD patients and inform advances in other inherited and neurodegenerative neurological disorders. Expand
Dietary Intake, Mediterranean Diet Adherence and Caloric Intake in Huntington’s Disease: A Review
TLDR
There was little consistency among study findings and it is important for more research to be conducted to have a better understanding of which dietary exposures are beneficial and may result delaying age of onset or disease progression in people with HD. Expand
The Prospective Huntington At-Risk Observational Study (PHAROS): The Emotional Well-Being, Safety and Feasibility of Long-Term Research Participation.
TLDR
The potentially vulnerable research participants in PHAROS showed good emotional tolerability and safety and long-term research participation of adults at risk for HD who choose not to undergo pre-symptomatic DNA testing is well tolerated, safe and feasible. Expand
Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington’s Disease
TLDR
The process, based on in vivo systems response profiling, by which pridopidine was discovered is described and its pharmacological profile is discussed, aiming to provide a model for the system-level effects, and a rationale for the use of pridipidine in patients affected by HD. Expand
Protective Effects of Antioxidants in Huntington’s Disease: an Extensive Review
TLDR
The present review aimed at delving into the abnormal cellular changes and energy kinetics of the neurons expressing the mHtt gene and the therapeutic roles of antioxidants in HD. Expand
Risk factors for suicidality in Huntington disease
TLDR
Psychiatric comorbidities in HD are predictive of suicidal behavior while participating in clinical trials, reinforcing the importance of clinical surveillance and treatment towards lessening risk during participation and perhaps beyond. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
Creatine supplementation in Huntington’s disease
TLDR
One year of Cr intake, at a rate that can improve muscle functional capacity in healthy subjects and patients with neuromuscular disease (5 g/day), did not improve functional, neuromUScular, and cognitive status in patients with stage I to III HD. Expand
PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington disease
TLDR
The results demonstrate the feasibility of prevention trials for HD and the safety of high-dose creatine, provide possible evidence of disease modification, support future studies of creatine, and illustrate the value of prodromal biomarkers. Expand
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.
TLDR
Among patients with early and treated Parkinson disease, treatment with creatine monohydrate for at least 5 years, compared with placebo did not improve clinical outcomes, and these findings do not support the use of creatine mon carbohydrate in patients with Parkinson disease. Expand
A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson Disease: 18-Month Results
TLDR
Data from this small, 18-month phase II trial of creatine and minocycline do not demonstrate safety concerns that would preclude a large, phase III efficacy trial, although the decreased tolerability of minocy Cline is a concern. Expand
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease
TLDR
Both creatine and minocycline should be considered for definitive Phase III trials to determine if they alter the long term progression of Parkinson disease (PD). Expand
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.
TLDR
Both creatine and minocycline should be considered for definitive Phase III trials to determine if they alter the long term progression of Parkinson disease (PD). Expand
A clinical trial of creatine in ALS
TLDR
Any beneficial effect of creatine at 5 g per day in ALS must be small, and other agents should be considered in future studies of therapeutic agents to address mitochondrial dysfunction in ALS. Expand
A randomized sequential trial of creatine in amyotrophic lateral sclerosis
TLDR
This double‐blind, placebo‐controlled, sequential clinical trial did not find evidence of a beneficial effect of creatine monohydrate on survival or disease progression in patients with ALS. Expand
Rate of functional decline in Huntington’s disease
TLDR
The comparable rates of decline on the TFC and the IS scores with other published studies suggest that these estimates of functional decline are representative of HD patients who are evaluated at HSG research sites, and should be considered in estimating statistical power and designing future therapeutic trials involving HD patients with early or moderately severe disease. Expand
High-dose creatine therapy for Huntington disease: A 2-year clinical and MRS study
TLDR
High-dose creatine was well tolerated, and total motor score, functional capacity, and neuropsychology testing remained stable at 12 months, and Serial 31P-MRS of muscle monitored changes in energy metabolism in vivo, and 1H-M RS was used to determine creatine levels in brain tissue. Expand
...
1
2
3
...